Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Basal Cell 1

Interventions

Nivolumab 6Specimen Handling 5Magnetic Resonance Spectroscopy 4Ipilimumab 4HhAntag691 4CTLA-4 Antigen 3Biopsy 3prednylidene 2deltacortene 2Standard of Care 2Prednisone 2talimogene laherparepvec 1sonidegib 1relatlimab 1daromun 1cemiplimab 1X-Rays 1Watchful Waiting 1Vitamin D 1Therapeutics 1Tacrolimus 1Sunscreening Agents 1Sirolimus 1Radiotherapy 1Practice Guidelines as Topic 1Photochemotherapy 1Observation 1Niacinamide 1Mohs Surgery 1MAPRE1 protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Basal Cell × daromun × 90 days × Clear all
NCT07227350 2026-06-02

L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

Philogen S.p.A.

Phase 2 Recruiting
180 enrolled
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡